Sponsored symposium Y-mAbs

Effective Administration and Management of Anti-GD2 Monoclonal Antibodies for Pediatric Neuroblastoma

Sponsored symposium by Y-mAbs
Monday 25 January 
20:00 – 21:00 hrs. 

Next-generation anti-GD2 therapies have expanded the treatment landscape for relapsed/refractory high-risk pediatric neuroblastoma. With few treatment options in this setting, anti-GD2 agents hold the promise of reducing the burden of care on patients and their families, including time spent in the hospital and financial, professional, and personal concerns.

To help achieve these goals, this activity will provide clinicians with critical updates on the scientific evidence related to these therapies. A multidisciplinary panel of experts in pediatric neuroblastoma and anti-GD2 therapy will review the nuances of treatment administration and delivery, along with the management of adverse events. Return to your practice with supportive-care protocols designed to facilitate safe and effective care for your patients with pediatric neuroblastoma, and to improve quality of life for these patients and their families.

Learning Objectives:

  • Review the historical evolution of anti-GD2 therapy and the rationale for novel therapies
  • Differentiate administration protocols for currently available anti-GD2 therapies
  • Assess the demands on the inpatient vs the outpatient treatment teams
  • Evaluate supportive-care strategies to manage the challenges of administration and treatment-related adverse effects of anti-GD2 therapy for pediatric neuroblastoma

Topics of Interest

  • Historical perspective of treatment of pediatric neuroblastoma
  • Rationale for new anti-GD2 therapy
  • Next-generation anti-GD2 monoclonal antibodies
  • Administration protocols for anti-GD2 monoclonal antibodies
  • Inpatient vs outpatient treatment administration
  • Supportive care for inpatient vs outpatient anti-GD2 therapy
    • Discomfort/pain, anaphylactic reactions, pyrexia, and respiratory depression
  • Team preparation for monitoring and effective management

Top Faculty/KOL:

  • Jaume Mora, MD, PhD
  • Daniel Morgenstern, MB BChir, PhD
  • Jennifer Cabral, H.BSc, RN


neuroblastoma, pediatric neuroblastoma, relapsed/refractory neuroblastoma, high-risk neuroblastoma, anti-GD2 therapy, anti-GD2 monoclonal antibodies, inpatient anti-GD2 therapy, outpatient anti-GD2 therapy, radioimmunotherapy, care coordination, patient/caregiver, disialoganglioside, naxitamab, GM-CSF, dinutuximab, omburtamab, hypersensitivity, pain, capillary leak syndrome